22.418 articles found

Use of an exogenous or endogenous inhibitor of N-methyltransferase for the manufacture of a medicament for therapy and prophylaxis of Parkinson's syndrome

WOLFF HANS UWE, WILHELM CHRISTOPH.

· 2005-06-24

New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.

Pinna A, Wardas J, Simola N, Morelli M.

Life Sci · 2005-06-23

DOI: 10.1016/j.lfs.2005.04.029PMID: 15979104

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.

Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A, TC-INIT Study Group.

Eur Neurol · 2005-06-20

DOI: 10.1159/000086479PMID: 15970632

Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation.

Lubik S, Fogel W, Tronnier V, Krause M, König J, Jost WH.

J Neural Transm (Vienna) · 2005-06-15

DOI: 10.1007/s00702-005-0310-8PMID: 15959852

Levodopa prodrugs, and compositions and uses thereof

XIANG JIA-NING, GALLOP MARK A, ZHOU CINDY X, NGUYEN MARK, DAI XUEDONG, LI JIANHUA, CUNDY KENNETH C, JUMBE NELSON L.

· 2005-06-03

Treatment of motor dysfunction in Parkinson's disease: an overview.

Thobois S, Delamarre-Damier F, Derkinderen P.

Clin Neurol Neurosurg · 2005-06-01

DOI: 10.1016/j.clineuro.2005.02.002PMID: 15885384

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E.

Parkinsonism Relat Disord · 2005-06-01

DOI: 10.1016/j.parkreldis.2004.11.005PMID: 15885624

Entacapone in the treatment of Parkinson's disease.

Schrag A.

Lancet Neurol · 2005-06-01

DOI: 10.1016/s1474-4422(05)70098-3PMID: 15907741

Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.

Domenici MR, Potenza RL, Martire A, Coccurello R, Pèzzola A, Reggio R, Tebano MT, Popoli P.

J Neurosci Res · 2005-06-01

DOI: 10.1002/jnr.20489PMID: 15880742

Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease.

Silva RM, Kuan CY, Rakic P, Burke RE.

Mov Disord · 2005-06-01

DOI: 10.1002/mds.20390PMID: 15719422

Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections.

Diepold K, Schütz B, Rostasy K, Wilken B, Hougaard P, Güttler F, Romstad A, Birk Møller L.

Mov Disord · 2005-06-01

DOI: 10.1002/mds.20416PMID: 15747353

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.

Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A.

Mov Disord · 2005-06-01

DOI: 10.1002/mds.20410PMID: 15747357